Precigen, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PGEN research report →
Companywww.precigen.com
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies.
- CEO
- Helen Sabzevari
- IPO
- 2013
- Employees
- 143
- HQ
- Germantown, MD, US
Price Chart
Valuation
- Market Cap
- $1.28B
- P/E
- -6.54
- P/S
- 40.60
- P/B
- 66.05
- EV/EBITDA
- -15.91
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 75.63%
- Op Margin
- -297.21%
- Net Margin
- -646.99%
- ROE
- -1768.51%
- ROIC
- -79.18%
Growth & Income
- Revenue
- $9.68M · 146.73%
- Net Income
- $-250,642,000 · -98.55%
- EPS
- $-1.41 · -200.00%
- Op Income
- $-106,600,000
- FCF YoY
- -17.03%
Performance & Tape
- 52W High
- $5.47
- 52W Low
- $1.28
- 50D MA
- $3.90
- 200D MA
- $3.90
- Beta
- 1.07
- Avg Volume
- 4.39M
Get TickerSpark's AI analysis on PGEN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 20, 26 | Lehr Donald P. | other | 358,000 |
| Apr 20, 26 | Lehr Donald P. | other | 107,000 |
| Apr 20, 26 | Sabzevari Helen | other | 1,366,000 |
| Apr 20, 26 | Sabzevari Helen | other | 410,000 |
| Apr 20, 26 | Shah Rutul R | other | 395,000 |
| Apr 20, 26 | Shah Rutul R | other | 118,000 |
| Apr 20, 26 | Tennant Phil | other | 385,000 |
| Apr 20, 26 | Tennant Phil | other | 115,000 |
| Apr 20, 26 | Thomasian Harry Jr. | other | 399,000 |
| Apr 20, 26 | Thomasian Harry Jr. | other | 120,000 |
Our PGEN Coverage
We haven't published any research on PGEN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PGEN Report →